je.st
news
Tag: rates
04.18.12 -- First 4x4 MIMO Field Trial: Stellar Data Rates Reported
2016-06-13 17:17:12| rfglobalnet Home Page
04/18/12 RF Globalnet Newsletter
Tags: data
field
rates
reported
Water Rates City Ordinance 2016-17
2016-06-07 18:20:56| PortlandOnline
PDF Document, 10,928kbCategory: Fees, Charges, SDCs
Tags: city
water
rates
ordinance
Low Interest Rates, Larger Loans Available for Green Apartments
2016-06-07 17:39:00| National Real Estate Investor
Both Fannie Mae and the Federal Housing Authority (FHA) have created loan programs that recognize the value of apartment properties that use less energy. read more
Tags: low
interest
larger
rates
KEYTRUDA (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
2016-06-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). These data will be presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 8:00 11:30 a.m. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Updated Findings from KEYNOTE-012 for KEYTRUDA (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
2016-06-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Data are being presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] next »